James Richard Porter Sells 17,890 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 17,890 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $1,741,054.80. Following the sale, the chief executive officer directly owned 288,172 shares in the company, valued at $28,044,899.04. This trade represents a 5.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

James Richard Porter also recently made the following trade(s):

• On Tuesday, January 6th, James Richard Porter sold 9,543 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total value of $927,197.88.
• On Thursday, October 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The shares were sold at an average price of $90.63, for a total transaction of $2,447,010.00.

Nuvalent Price Performance

Shares of NASDAQ:NUVL traded up $9.62 during trading on Wednesday, hitting $106.82. 895,694 shares of the company were exchanged, compared to its average volume of 779,373. The firm’s 50 day moving average price is $102.57 and its 200-day moving average price is $88.78. Nuvalent, Inc. has a 12-month low of $55.53 and a 12-month high of $112.88. The stock has a market capitalization of $7.77 billion, a P/E ratio of -20.08 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same quarter in the previous year, the firm earned ($1.28) EPS. As a group, equities research analysts anticipate that Nuvalent, Inc. will post -3.86 EPS for the current year.

Hedge Funds Weigh In On Nuvalent

A number of hedge funds and other institutional investors have recently bought and sold shares of NUVL. GAMMA Investing LLC raised its position in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Nuvalent during the third quarter worth about $38,000. Eastern Bank acquired a new position in shares of Nuvalent during the third quarter worth about $52,000. Persistent Asset Partners Ltd purchased a new position in Nuvalent during the second quarter worth about $88,000. Finally, Farther Finance Advisors LLC lifted its position in Nuvalent by 9,230.8% in the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after purchasing an additional 1,200 shares during the period. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a research note on Wednesday, October 8th. Cantor Fitzgerald assumed coverage on shares of Nuvalent in a research report on Wednesday, October 15th. They set an “overweight” rating and a $135.00 target price on the stock. UBS Group reiterated a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. Guggenheim increased their price target on shares of Nuvalent from $125.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, Barclays set a $152.00 price objective on shares of Nuvalent in a research note on Monday, November 17th. Fifteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $138.33.

Key Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.